These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20569704)

  • 1. Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trial.
    Abraham WT; Gras D; Yu CM; Guzzo L; Gupta MS;
    Am Heart J; 2010 Jun; 159(6):944-948.e1. PubMed ID: 20569704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold M; Abraham WT; Daubert JC;
    Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of AV and VV delays in the real-world CRT patient population: an international survey on current clinical practice.
    Gras D; Gupta MS; Boulogne E; Guzzo L; Abraham WT
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S236-9. PubMed ID: 19250104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automatic optimization of cardiac resynchronization therapy using SonR-rationale and design of the clinical trial of the SonRtip lead and automatic AV-VV optimization algorithm in the paradym RF SonR CRT-D (RESPOND CRT) trial.
    Brugada J; Brachmann J; Delnoy PP; Padeletti L; Reynolds D; Ritter P; Borri-Brunetto A; Singh JP
    Am Heart J; 2014 Apr; 167(4):429-36. PubMed ID: 24655689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial.
    Krum H; Lemke B; Birnie D; Lee KL; Aonuma K; Starling RC; Gasparini M; Gorcsan J; Rogers T; Sambelashvili A; Kalmes A; Martin D
    Am Heart J; 2012 May; 163(5):747-752.e1. PubMed ID: 22607850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study.
    Boriani G; Müller CP; Seidl KH; Grove R; Vogt J; Danschel W; Schuchert A; Djiane P; Biffi M; Becker T; Bailleul C; Trappe HJ;
    Am Heart J; 2006 May; 151(5):1050-8. PubMed ID: 16644335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pacing Evaluation-Atrial SUpport Study in Cardiac Resynchronization Therapy (PEGASUS CRT): design and rationale.
    Martin DO; Stolen KQ; Brown S; Yu Y; Christie C; Doshi SK; Smith JM; Gold MR; Day JD
    Am Heart J; 2007 Jan; 153(1):7-13. PubMed ID: 17174627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale.
    Curtis AB; Adamson PB; Chung E; Sutton MS; Tang F; Worley S
    J Cardiovasc Electrophysiol; 2007 Sep; 18(9):965-71. PubMed ID: 17655677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-site versus standard cardiac resynchronization therapy study (TRUST CRT): clinical rationale, design, and implementation.
    Lenarczyk R; Kowalski O; Sredniawa B; Pruszkowska-Skrzep P; Pluta S; Sokal A; Kukulski T; Stabryła-Deska J; Woźniak A; Kowalczyk J; Zielińska T; Mazurek M; Streb W; Zembala M; Kalarus Z
    J Cardiovasc Electrophysiol; 2009 Jun; 20(6):658-62. PubMed ID: 19635069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical effects of programmer-guided atrioventricular and interventricular delay optimization: Intracardiac electrography versus echocardiography for cardiac resynchronization therapy in patients with heart failure.
    Wang D; Yu H; Yun T; Zang H; Yang G; Wang S; Wang Z; Jing Q; Han Y
    J Int Med Res; 2013 Feb; 41(1):115-22. PubMed ID: 23569136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy: device-based medicine for heart failure.
    Philippon F
    J Card Surg; 2004; 19(3):270-4. PubMed ID: 15151661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved response to cardiac resynchronization therapy through optimization of atrioventricular and interventricular delays using acoustic cardiography: a pilot study.
    Toggweiler S; Zuber M; Kobza R; Roos M; Jamshidi P; Meier R; Erne P
    J Card Fail; 2007 Oct; 13(8):637-42. PubMed ID: 17923355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of device programming for cardiac resynchronization therapy.
    Burri H; Sunthorn H; Shah D; Lerch R
    Pacing Clin Electrophysiol; 2006 Dec; 29(12):1416-25. PubMed ID: 17201852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure.
    Zaręba W
    Cardiol J; 2010; 17(6):543-8. PubMed ID: 21154255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial.
    Padeletti L; Muto C; Maounis T; Schuchert A; Bongiorni MG; Frank R; Vesterlund T; Brachmann J; Vicentini A; Jauvert G; Tadeo G; Gras D; Lisi F; Dello Russo A; Rey JL; Boulogne E; Ricciardi G;
    Am Heart J; 2008 Sep; 156(3):520-6. PubMed ID: 18760135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
    Pires LA; Abraham WT; Young JB; Johnson KM;
    Am Heart J; 2006 Apr; 151(4):837-43. PubMed ID: 16569543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
    Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
    Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a randomized trial of biventricular pacing in Canada.
    Bentkover JD; Dorian P; Thibault B; Gardner M
    Pacing Clin Electrophysiol; 2007 Jan; 30(1):38-43. PubMed ID: 17241313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
    Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
    J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.